Table 1.
Baseline demographic and clinical characteristics
| Characteristic | Low AKR1C4 expression (n = 105) | High AKR1C4 expression (n = 74) | P a |
|---|---|---|---|
| Age | 0.970 | ||
| Median (Range) | 50 (20–79) | 49.5(19–78) | |
| Sex | 0.914 | ||
| Male | 83 (79.0%) | 58 (78.4%) | |
| Female | 22 (21.0%) | 16 (21.6%) | |
| T stageb | 0.175 | ||
| 1 | 5 (4.8%) | 6 (8.1%) | |
| 2 | 21 (20.0%) | 7 (9.5%) | |
| 3 | 46 (43.8%) | 40 (54.1%) | |
| 4 | 33 (31.4%) | 21 (28.4%) | |
| N stageb | 0.847 | ||
| 0 | 24 (22.9%) | 16 (21.6%) | |
| 1 | 32 (30.5%) | 23 (31.1%) | |
| 2 | 32 (30.5%) | 26 (35.1%) | |
| 3 | 17 (16.2%) | 9 (12.2%) | |
| Disease stageb | 0.014 | ||
| I | 1 (1.0%) | 4 (5.4%) | |
| II | 18 (17.1%) | 4 (5.4%) | |
|
III IVa |
41 (39.0%) 45 (42.9%) |
39 (52.7%) 27 (36.5%) |
|
|
WHO type II III |
4 (3.8%) 101 (96.2%) |
2 (2.7%) 72 (97.3%) |
1.000 |
|
EBV DNA (copies/mL) < 4000 ≥ 4000 |
67 (63.8%) 38 (36.2%) |
41 (55.4%) 33 (44.6%) |
0.258 |
|
VCA-IgA < 1:80 ≥ 1:80 |
32 (30.5%) 73 (69.5%) |
20 (27.0%) 54 (73.0%) |
0.617 |
| EA-IgA | 0.509 | ||
| < 1:10 | 42 (40.0%) | 26 (35.1%) | |
| ≥ 1:10 | 63 (60.0%) | 48 (64.9%) | |
| CRP (g/ml) | 0.150 | ||
| < 3.00 | 72 (68.6%) | 43 (58.1%) | |
| ≥ 3.00 | 33 (31.4%) | 31 (41.9%) | |
| BMI (kg/m2) | 0.228 | ||
| < 18.5 | 11 (10.5%) | 4 (5.4%) | |
| ≥ 18.5 | 94 (89.5%) | 70 (94.6%) | |
| Smoking status | 0.972 | ||
| Yes | 40 (38.1%) | 28 (37.8%) | |
| No | 65 (61.9%) | 46 (62.2%) |
Abbreviations: BMI Body mass index, CRP C-reactive protein, EA Early antigen, EBV DNA Epstein-Barr virus deoxyribonucleic acid, VCA Viral capsid antigen, WHO World Health Organization
aBoldface letter: significant
bAccording to the 8th edition of the American Joint Committee on Cancer/Union for International Cancer Control staging system